Maxine Taylor

638 total citations
14 papers, 436 citations indexed

About

Maxine Taylor is a scholar working on Pharmacology, Oncology and Molecular Biology. According to data from OpenAlex, Maxine Taylor has authored 14 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pharmacology, 5 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Maxine Taylor's work include Pharmacogenetics and Drug Metabolism (6 papers), Drug-Induced Hepatotoxicity and Protection (5 papers) and Drug Transport and Resistance Mechanisms (4 papers). Maxine Taylor is often cited by papers focused on Pharmacogenetics and Drug Metabolism (6 papers), Drug-Induced Hepatotoxicity and Protection (5 papers) and Drug Transport and Resistance Mechanisms (4 papers). Maxine Taylor collaborates with scholars based in United Kingdom, United States and Switzerland. Maxine Taylor's co-authors include Jackie C. Bloomer, Stephan Duparc, Andrew W. Harrell, Gavin Koh, Harma Ellens, Stephen E. Clarke, Steven J. Stanway, Liangfu Chen, Colin H. Macphee and Ivan L. Pinto and has published in prestigious journals such as Journal of Medicinal Chemistry, Antimicrobial Agents and Chemotherapy and Molecular Pharmacology.

In The Last Decade

Maxine Taylor

14 papers receiving 420 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maxine Taylor United Kingdom	12	133	111	83	77	75	14	436
Daria Stypinski United States	14	125 0.9×	81 0.7×	169 2.0×	59 0.8×	72 1.0×	30	562
Ellen A. Cannady United States	11	74 0.6×	87 0.8×	103 1.2×	59 0.8×	121 1.6×	21	456
Marianne K. DeGorter Canada	11	78 0.6×	205 1.8×	148 1.8×	32 0.4×	165 2.2×	16	644
Tomáš Smutný Czechia	17	219 1.6×	224 2.0×	162 2.0×	24 0.3×	68 0.9×	33	710
Roman Tremmel Germany	13	197 1.5×	186 1.7×	97 1.2×	34 0.4×	18 0.2×	33	481
Henrike Bruckmueller Germany	16	126 0.9×	194 1.7×	241 2.9×	54 0.7×	42 0.6×	25	600
Feng Deng Finland	11	71 0.5×	87 0.8×	172 2.1×	24 0.3×	64 0.9×	19	357
Archie Thurston United States	12	72 0.5×	166 1.5×	124 1.5×	18 0.2×	30 0.4×	18	496
Yasuo Kodama Japan	13	67 0.5×	189 1.7×	62 0.7×	39 0.5×	38 0.5×	42	452
Annelies L. Draaisma Netherlands	8	227 1.7×	118 1.1×	210 2.5×	35 0.5×	115 1.5×	9	565

Countries citing papers authored by Maxine Taylor

Since Specialization

Citations

This map shows the geographic impact of Maxine Taylor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maxine Taylor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maxine Taylor more than expected).

Fields of papers citing papers by Maxine Taylor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maxine Taylor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maxine Taylor. The network helps show where Maxine Taylor may publish in the future.

Co-authorship network of co-authors of Maxine Taylor

This figure shows the co-authorship network connecting the top 25 collaborators of Maxine Taylor. A scholar is included among the top collaborators of Maxine Taylor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maxine Taylor. Maxine Taylor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Vélez, Iván Darío, Tran Tinh Hien, Justin A. Green, et al.. (2021). Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial. The Lancet Child & Adolescent Health. 6(2). 86–95. 7 indexed citations

Walker, Tracy, Maxine Taylor, Martin Vidgeon-Hart, et al.. (2021). Evaluation of a Three-Dimensional Primary Human Hepatocyte Spheroid Model: Adoption and Industrialization for the Enhanced Detection of Drug-Induced Liver Injury. Chemical Research in Toxicology. 34(12). 2485–2499. 16 indexed citations

Patel, Aarti, Robert Wilson, Andrew W. Harrell, et al.. (2020). Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations. Drug Metabolism and Disposition. 48(4). 307–316. 6 indexed citations

Goyal, Navin, Khadeeja Mohamed, Katie Rolfe, et al.. (2018). Application of the Stable Isotope Label Approach in Clinical Development—Supporting Dissolution Specifications for a Commercial Tablet Product with Tafenoquine, a Long Half-life Compound. The AAPS Journal. 20(4). 74–74. 12 indexed citations

Jean, Pamela L. St., Zhengyu Xue, Nick Carter, et al.. (2016). Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial. Malaria Journal. 15(1). 97–97. 61 indexed citations

Green, Justin A., Khadeeja Mohamed, Navin Goyal, et al.. (2016). Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy. 60(12). 7321–7332. 23 indexed citations

Taylor, S., Emmanuel H. Demont, James R. Gray, et al.. (2015). Navigating CYP1A Induction and Arylhydrocarbon Receptor Agonism in Drug Discovery. A Case History with S1P ₁ Agonists. Journal of Medicinal Chemistry. 58(20). 8236–8256. 13 indexed citations

Dave, Mehul, Graeme Young, Harma Ellens, et al.. (2013). Disposition and Metabolism of Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Humans. Drug Metabolism and Disposition. 42(3). 415–430. 13 indexed citations

Iusuf, Dilek, Anita van Esch, Maxine Taylor, et al.. (2013). Murine Oatp1a/1b Uptake Transporters Control Rosuvastatin Systemic Exposure Without Affecting Its Apparent Liver Exposure. Molecular Pharmacology. 83(5). 919–929. 33 indexed citations

10.

Reese, Melinda J., Andrew W. Harrell, Maxine Taylor, et al.. (2012). Preclinical Strategy to Reduce Clinical Hepatotoxicity Using in Vitro Bioactivation Data for >200 Compounds. Chemical Research in Toxicology. 25(10). 2067–2082. 84 indexed citations

11.

Reese, Melinda J., Jeffrey L. Ambroso, Andrew W. Harrell, et al.. (2010). An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development. Chemico-Biological Interactions. 192(1-2). 60–64. 21 indexed citations

12.

Bloomer, Jackie C., Murray J. B. Brown, Hung‐Yuan Cheng, et al.. (2003). The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2. Bioorganic & Medicinal Chemistry Letters. 13(6). 1067–1070. 100 indexed citations

13.

Bloomer, Jackie C., Murray J. B. Brown, Hung‐Yuan Cheng, et al.. (2002). The discovery of SB-435495. Bioorganic & Medicinal Chemistry Letters. 12(18). 2603–2606. 34 indexed citations

14.

Bloomer, Jackie C., Helen Boyd, Robert J. Ife, et al.. (2001). 1-(Arylpiperazinylamidoalkyl)-pyrimidones: orally active inhibitors of lipoprotein-associated phospholipase A 2. Bioorganic & Medicinal Chemistry Letters. 11(14). 1925–1929. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact